Send to

Choose Destination
Mod Pathol. 1999 Aug;12(8):827-34.

Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside.

Author information

Health Sciences Center, Sunnybrook and Women's College, Department of Pathology, University of Toronto, Canada.


Molecular alterations in breast cancer are being incorporated into the development of new treatment strategies. The HER-2/neu oncogene has been extensively investigated as a prognostic factor and recently as a predictor of response to chemotherapy or endocrine therapy. The development of a humanized anti-HER-2 monoclonal antibody (Herceptin) and the encouraging results obtained in the treatment of patients with HER-2 overexpressing metastatic breast cancer with this antibody have resulted in renewed interest in HER-2/neu. This article reviews the current knowledge of HER-2/neu both as a prognostic and a predictive factor. Problems associated with the standardization of the methodology for assessing HER-2/neu status and clinically significant cut-off points are addressed.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center